Abstract
This is the fourth article in a four-part series of nuclear medicine updates. Upon completion of this article, the reader will have: (1) an understanding of the various phases involved in investigational new drugs (IND), (2) a reference for preparing an IND, and (3) an awareness of the common pitfalls associated with preparing and fulfilling the commitment of an IND.